Opinion|Videos|November 19, 2026

Speeding Up NSCLC Treatment: AI Scheduling, Subcutaneous Dosing, and Payer Transparency

AI-assisted scheduling, faster subcutaneous administration, and greater payer transparency are among the practical strategies pharmacists describe for easing chair shortages and avoiding prior authorization surprises.

In "Speeding Up NSCLC Treatment: AI Scheduling, Subcutaneous Dosing, and Payer Transparency," our experts turn to practical strategies for easing those barriers.

Dr. Cass asks what needs to be addressed to overcome these barriers and invites the panelists to share ideas for solving them.

Dr. Luon speaks first to chair time. His center is working with a program that uses an AI model to optimize patient scheduling, including how much time to book for each type of treatment. The work is still in progress. The team hopes it will help them make the best use of nurses, chairs, and other resources.

He also points to subcutaneous formulations. Although amivantamab is not an immunotherapy, he says the panel would agree its subcutaneous form helped greatly, since day one used to take six to eight hours depending on tolerance. Immune checkpoint inhibitors now have subcutaneous options as well, but the time difference is smaller. Many immunotherapies already run over 30 minutes, and some run over an hour. Even so, he sees an advantage in faster administration and hopes upcoming formulations will shorten chair times further.

Dr. Lynch turns to insurance. Once her team chooses a regimen, they schedule the patient and start prior authorization, expecting to proceed within a week. Three days into the process, an email may arrive saying the immunotherapy must go through the pharmacy benefit and be white-bagged, or that the insurer prefers a different checkpoint inhibitor. Staff must then rework the plan and pursue a new prior authorization through another part of the benefit, often with very high co-pays.

She therefore asks for greater transparency from payers. Teams should be able to see up front when a drug requires the pharmacy benefit or when the payer has a preferred agent. At present, she says, those details are buried on insurer websites or available only if the patient calls. Dr. Cass agrees that clearer requirements and turnaround times would help patients.

The next episode, "Biomarker Testing Delays in NSCLC: Tissue, Liquid Biopsy, and Treatment Start," focuses on the biggest bottlenecks to starting treatment, beginning with testing delays.

Related to this article

Two pharmacists in a pharmacy -- Image credit: Krakenimages.com | stock.adobe.com
Balanced exposure to clinical and nonclinical careers, timed to each pathway's application calendar and built into each curriculum's structure, can help pharmacy students choose their next step deliberately.